Company profile for Annexon Biosciences

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Our mission is to develop disease-modifying therapeutics for patients suffering with classical complement-mediated autoimmune, ophthalmic and neurodegenerative disorders. Backed by a team with deep experience in autoimmune and neurodegenerative diseases, our mission is to rapidly advance disease-modifying therapeutics for patients with complement-mediated autoimmune and neurodegenerative disorders. Annexon’s leadership has a...
Our mission is to develop disease-modifying therapeutics for patients suffering with classical complement-mediated autoimmune, ophthalmic and neurodegenerative disorders. Backed by a team with deep experience in autoimmune and neurodegenerative diseases, our mission is to rapidly advance disease-modifying therapeutics for patients with complement-mediated autoimmune and neurodegenerative disorders. Annexon’s leadership has an extensive and successful track-record of discovering, developing and commercializing breakthrough therapeutics for debilitating disease.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
180 Kimball Way, 2nd Floor, Suite 200 South San Francisco, CA 94080
Telephone
Telephone
650.822.5500
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/14/3188597/0/en/Annexon-Announces-Closing-of-Public-Offering-and-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shares-for-Gross-Proceeds-of-86-25-Million.html

GLOBENEWSWIRE
14 Nov 2025

https://www.globenewswire.com/news-release/2025/11/12/3186813/0/en/Annexon-Announces-Proposed-Public-Offering-of-Common-Stock-and-Pre-Funded-Warrants.html

GLOBENEWSWIRE
12 Nov 2025

https://www.globenewswire.com/news-release/2025/11/10/3185058/0/en/Annexon-Reports-Third-Quarter-2025-Financial-Results-Portfolio-Progress-and-Key-Anticipated-Milestones.html

GLOBENEWSWIRE
10 Nov 2025

https://www.globenewswire.com/news-release/2025/08/27/3139956/0/en/Annexon-Biosciences-to-Participate-in-Upcoming-September-Investor-Conferences.html

GLOBENEWSWIRE
27 Aug 2025

https://www.globenewswire.com/news-release/2025/08/14/3133863/0/en/Annexon-Reports-Second-Quarter-2025-Financial-Results-Portfolio-Progress-and-Key-Anticipated-Milestones.html

GLOBENEWSWIRE
14 Aug 2025

https://www.globenewswire.com/news-release/2025/08/07/3129764/0/en/Annexon-Selected-by-EMA-to-Participate-in-Product-Development-Coordinator-Pilot-for-Vonaprument-ANX007-for-Dry-Age-Related-Macular-Degeneration-with-Geographic-Atrophy.html

GLOBENEWSWIRE
07 Aug 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty